Hazard ratios (HR) with 95% confidence intervals (95%CI) for the risk of interstitial lung disease (ILD) and acute or chronic respiratory failure in 30,512 patients with rheumatoid arthritis up to 5 years after diagnosis.
| ILD (incl. drug-induced cases) | 1 year of follow up | 5 years of follow up | ||
|---|---|---|---|---|
| Events, N | HR (95% CI) | Events, N | HR (95% CI) | |
| Methotrexate, ≥1 redeemed prescription(s) vs. none | 62 | 1.03 (0.71 to 1.48) | 166 | 1.00 (0.78 to 1.27) |
| Sulphasalazine, ≥1 redeemed prescription(s) vs. none | 21 | 0.88 (0.54 to 1.43) | 90 | 1.14 (0.89 to 1.48) |
| Amiodarone and/or nitrofurantoin, ≥1 redeemed prescription(s) vs. none | 1 | 0.57 (0.08 to 4.10) | 7 | 0.65 (0.31 to 1.38 |
| Women | 72 | Ref. | 155 | Ref. |
| Men | 55 | 1.51 (1.06 to 2.16) | 130 | 1.74 (1.38 to 2.21) |
| Acute or chronic respiratory failure | 1-year of follow up | 5-years of follow up | ||
| Events, N | HR (95% CI) | Events, N | HR (95% CI) | |
| Methotrexate, ≥1 redeemed prescription(s) vs. none | 36 | 0.48 (0.32 to 0.73) | 158 | 0.54 (0.43 to 0.67) |
| Sulphasalazine, ≥1 redeemed prescription(s) vs. none | 14 | 0.70 (0.39 to 1.26) | 99 | 1.09 (0.86 to 1.38) |
| Amiodarone and/or nitrofurantoin, ≥1 redeemed prescription(s) vs. none | 6 | 3.01 (1.31 to 6.94) | 22 | 1.33 (0.86 to 2.06) |
| Women | 71 | Ref. | 239 | Ref. |
| Men | 38 | 1.07 (0.72 to 1.59) | 120 | 1.04 (0.83 to 1.29) |